InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,613.34
(
-0.06%
)
US TECH 100
19,022.40
(
0.05%
)
Dow Jones
41,158.78
(
-0.20%
)
Brent Oil
79.14
(
-1.41%
)
Bitcoin
61,643.38
(
-1.96%
)
Post# of 29566
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120334
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 28720

Wednesday, 10/18/2023 9:41:35 AM

Wednesday, October 18, 2023 9:41:35 AM

Post# of 29566
ABT 3Q23 Results by Business Segment 
  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency) 
 Medical devices*  42%       +15% 
 Nutrition         24%       +18% 
 Diagnostics       20%       -32%† 
 Branded generics  13%       +18%
62% of overall corporate sales were ex-US.

*Includes diabetes care.

†3Q23 COVID-diagnostics sales were $305M (12% of total 2Q23 diagnostic sales) vs $1.7B in 3Q22; excluding COVID diagnostics, 3Q23 diagnostics sales were +10% YoY.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up